We encourage all attendees to complete the anonymous conference evaluation. Your candid input on the 2022 ASCP Annual Meeting is appreciated as we strive to improve the conference each year! Please do not complete the evaluation until you have watched all desired sessions so you can evaluate the meeting in its entirety. Please note you cannot access the evaluation while logged into the conference platform. You will need to either logout first OR copy and paste the following link into an incognito browser window:

https://ascp.societyconference.com/conf/#evaluation/conf10034

After your evaluation is complete, you will be asked if you would like to apply for education hours or request a certificate of attendance. There is a $40 charge to apply for CE credits. There is no charge to request a certificate of attendance. If yes, you will be prompted to login to your account to attest your hours.
The deadline to complete your evaluation and apply for credits or certificate of attendance is July 01, 2022 at 10pm EDT.

The ASCP Annual Meeting is the premier meeting each year in the field of psychopharmacology. Bringing together representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry to discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Susan Kornstein and Mark Rapaport with representation of the sectors that are part of the ASCP community lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2022 Steering Committee. A Program Committee under the leadership of Drs. Erika Saunders and Lee Cohen are responsible for the review of all program submissions.

The ASCP Annual Meeting brings together over 1200 academic and industry investigators, research pharmacists, and clinicians, including competitively selected New Investigator awardees.  ASCP is joined by federal partners, the National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute on Alcohol Abuse and Alcoholism, (NIAAA) and the Food and Drug Administration (FDA) to organize a program that emphasizes the presentation of information that has not been previously published or presented. For more information about the history and purpose of the ASCP Annual Meeting please click here.

In recent years, the ASCP Annual Meeting focus has been expanded to address a number of timely issues relevant to clinical research in psychiatry, including the translation of research into practice, the importance of regulatory issues, and pharmacogenetics and other means to personalizing interventions.

• Late-Breaking Posters – Late-breaking science included in the poster session.
• Poster Presentation – Poster board presentation in a general session.
• Individual Research Report – Selected by the Program Committee, these are 10 minute oral presentation with 5 minutes Q&A from the audience.
• Panel Sessions – Have a Chair, a minimum of 3 Speakers but no more than 4 speakers, and a discussant. A co-chair is optional. Panel sessions are 1.5 hours in length.
• Workshop Sessions – Integrative session with a chair and no more than 8 participants. A discussant and co-chair is optional. Workshop sessions are 2 hours in length.
• Pharmaceutical Pipeline Presentations– A Pharmaceutical Pipeline report will be a 10 minute presentation and will also have the opportunity to present their research as a poster presentation. A Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on any CNS compound for which Phase 3 data has not been presented. The goal is to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest.